Phathom Pharmaceuticals Inc (PHAT) Stock Price, Quote & News

Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heart...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 742 8466

Website: www.phathompharma.com

Address:

100 Campus Drive, Suite 102, Florham Park, United States

LiquidThetaOptions Nov. 14 at 9:27 PM

💎 LiquidTheta® Live Actionable Trade Asset: $PHAT Contracts: $PHAT January 15, 2027 $15 Calls Scale in: $5.04- $6.16 Scale out: $19.60-$33.60 Profit Potential : 94% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

HedgeAlerts Nov. 14 at 6:20 PM

Hedge Alert Live - Protect Your Portfolio Contract: $PHAT $15.00 Put · NOV 21, 2025 Exp Entry Price: $0.75 - $4.90 Exit Price Target: $1.53 Profit Margin: +104% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

RonIsWrong Nov. 14 at 4:43 PM

$PHAT come on, push it

2 · Reply

Joe_90_ Nov. 14 at 4:21 PM

$PHAT 54916 shares avail to short, squeeze starting 😉 bears will feel like this dog

1 · Reply

HedgeAlerts Nov. 14 at 7:40 AM

Hedge Alert Live - Protect Your Portfolio Contract: $PHAT $12.50 Put · NOV 21, 2025 Exp Entry Price: $0.05 - $0.90 Exit Price Target: $0.08 Profit Margin: +57% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Morrito23 Nov. 13 at 8:37 PM

$PHAT “Quick, let’s make it seem like this can’t go over $15” -shorts, probably This was our first time re-testing that zone since our ER. Not really surprised it didn’t hold. Shorts, paired with some quick profit takers, and low volume, will bring us down in a blink.

1 · Reply

Snatchman Nov. 13 at 7:27 PM

$PHAT 15... Let's gear up for short submission mode

0 · Reply

KLD57 Nov. 13 at 6:08 PM

$PHAT yo I bought this stock at 2.60 earlier this year how we feeling ?????

1 · Reply

Snatchman Nov. 13 at 3:20 PM

$PHAT I think once $15 prints, that will be the trigger point of some increased panic among the short community.

2 · Reply

Joe_90_ Nov. 12 at 9:47 PM

$PHAT Stifel Health Conference on line now

1 · Reply

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Nov 3, 2025, 7:59 AM EST - 11 days ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Oct 30, 2025, 1:26 PM EDT - 15 days ago

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 7:00 AM EDT - 15 days ago

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 25, 2025, 9:59 AM EDT - 20 days ago

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Oct 23, 2025, 8:00 AM EDT - 22 days ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Oct 20, 2025, 8:00 AM EDT - 25 days ago

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Oct 6, 2025, 1:29 PM EDT - 5 weeks ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Oct 6, 2025, 8:00 AM EDT - 5 weeks ago

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Aug 20, 2025, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

Aug 7, 2025, 10:51 PM EDT - 3 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 6:59 AM EDT - 3 months ago

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 28, 2025, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Jun 25, 2025, 4:54 AM EDT - 5 months ago

Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism

Jun 23, 2025, 4:15 PM EDT - 5 months ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 23, 2025, 7:59 AM EDT - 5 months ago

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

SAGE

Jun 16, 2025, 8:00 AM EDT - 5 months ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Jun 10, 2025, 10:08 AM EDT - 5 months ago

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy

Jun 6, 2025, 12:27 PM EDT - 5 months ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

May 1, 2025, 12:09 PM EDT - 7 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ITCI

Apr 28, 2025, 7:59 AM EDT - 7 months ago

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Apr 23, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Apr 17, 2025, 8:00 AM EDT - 7 months ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

HLVX

Apr 16, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

CDTX

Apr 3, 2025, 8:00 AM EDT - 8 months ago

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 8 months ago

Phathom Pharmaceuticals Announces Leadership Succession

Mar 31, 2025, 7:59 AM EDT - 8 months ago

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Mar 6, 2025, 12:13 PM EST - 9 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 8:00 AM EST - 9 months ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:00 AM EST - 9 months ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Jan 29, 2025, 8:00 AM EST - 10 months ago

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Dec 11, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Nov 10, 2024, 3:54 AM EST - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Oct 27, 2024, 12:00 PM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Aug 10, 2024, 2:52 PM EDT - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Jun 26, 2024, 6:11 AM EDT - 1 year ago

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

May 11, 2024, 7:03 PM EDT - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript

May 9, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Mar 18, 2024, 1:19 AM EDT - 1 year ago

Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion

Mar 7, 2024, 2:11 PM EST - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 29, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

LiquidThetaOptions Nov. 14 at 9:27 PM

0 · Reply

HedgeAlerts Nov. 14 at 6:20 PM

0 · Reply

RonIsWrong Nov. 14 at 4:43 PM

$PHAT come on, push it

2 · Reply

Joe_90_ Nov. 14 at 4:21 PM

$PHAT 54916 shares avail to short, squeeze starting 😉 bears will feel like this dog

1 · Reply

HedgeAlerts Nov. 14 at 7:40 AM

0 · Reply

Morrito23 Nov. 13 at 8:37 PM

1 · Reply

Snatchman Nov. 13 at 7:27 PM

$PHAT 15... Let's gear up for short submission mode

0 · Reply

KLD57 Nov. 13 at 6:08 PM

$PHAT yo I bought this stock at 2.60 earlier this year how we feeling ?????

1 · Reply

Snatchman Nov. 13 at 3:20 PM

$PHAT I think once $15 prints, that will be the trigger point of some increased panic among the short community.

2 · Reply

Joe_90_ Nov. 12 at 9:47 PM

$PHAT Stifel Health Conference on line now

1 · Reply

Ecryder Nov. 12 at 8:49 PM

$PHAT nice

0 · Reply

Snatchman Nov. 12 at 8:35 PM

$PHAT

0 · Reply

LiquidThetaOptions Nov. 12 at 4:46 PM

💎 LiquidTheta® Live Actionable Trade Asset: $PHAT Contracts: $PHAT January 15, 2027 $15 Calls Scale in: $4.93- $6.02 Scale out: $19.16-$32.85 Profit Potential : 102% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

StockConsultant Nov. 12 at 2:31 PM

$PHAT Phathom Pharmaceuticals stock, watch for a narrow range breakout

0 · Reply

Joe_90_ Nov. 12 at 11:22 AM

$PHAT folks to prevent your shares being lent out, i'd suggest putting them sell limit $21 GTC and keep an eye on the price and adjust accordingly, you don't want the shares to be unintentionally sold like what happened to me around the earnings call.

1 · Reply

Morrito23 Nov. 11 at 10:44 PM

$PHAT short interest went down about 500k shares…days to cover went up. With the lower volume days we’ve been seeing, shorts need to be very careful of when they decide to cover. Any action can move our price dramatically. What an interesting little predicament they find themselves in.

1 · Reply

BallisticShart Nov. 11 at 10:42 PM

$PHAT

0 · Reply

LiquidThetaOptions Nov. 11 at 8:31 PM

💎 LiquidTheta® Live Actionable Trade Asset: $PHAT Contracts: $PHAT January 15, 2027 $15 Calls Scale in: $4.70- $5.75 Scale out: $18.29-$31.35 Profit Potential : 312% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Joe_90_ Nov. 11 at 6:50 PM

$PHAT next stop

0 · Reply

Snatchman Nov. 11 at 4:49 PM

$PHAT Did shorts cover yet?

2 · Reply

Iightning Nov. 11 at 3:32 PM

1ightning® Options Trade Alert (Actionable) | Buy $PHAT Nov 21 $15 Call | Enter: $1.00 Exit: $1.42 | Profit: 41.60% ROI | https://1ightning.com

0 · Reply

SuperGreenToday Nov. 10 at 6:08 PM

$PHAT Share Price: $13.84 Contract Selected: May 15, 2026 $15 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.27 – $2.78 Potential Upside: 68% ROI Time to Expiration: 185 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Market Cap	1.06B
Revenue (ttm)	55.25M
Net Income (ttm)	-334.33M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-605.12%
Debt to Equity Ratio	-0.49

Volume	971,400
Avg Vol	1,156,164
Day's Range	N/A - N/A
Shares Out	71.14M
Stochastic %K	76%
Beta	0.47
Analysts	Strong Sell
Price Target	$23.12